Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Opening and detailed source regimens are retained separately where wording differs. Historical infection regimens are not labeled current guideline therapy.
Check source scope before reading a dose
NIH OI: Fluconazole
Product / population
Adults with HIV.
Renal method
NIH table: CrCl or eGFR; not interchangeable. Not CRRT.
Source revision
Updated April 23, 2025; reviewed March 16, 2026
Retrieved
2026-09-05
Local review status
Source-read local summary; source-specific recommendations are not automatically interchangeable.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
Nondialysis percentage differs below CrCl 10
The RX table retains 50% of the indication dose at CrCl <=50 without dialysis. UCSF separates CrCl <10 and uses 25%. Its continuous-dialysis guidance is specifically qualified by CVVHD evidence.
What to reconcile: Select one applicable complete regimen. Do not combine a label percentage with a different institutional dialysis interval.
Renal method: NIH table: CrCl or eGFR; not interchangeable. Not CRRT. Source date: Updated April 23, 2025; reviewed March 16, 2026 Retrieved: 2026-09-05
Source-read local summary; source-specific recommendations are not automatically interchangeable.
Dose and kidney adjustment
Usual OI dose: 200-1,200 mg orally/IV daily, indication-dependent. Renal estimate <=50 mL/min: full initial dose, then half-dose maintenance daily. Intermittent HD: full initial dose, then full indication-specific dose three times weekly after HD.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.